JP6998655B2 - 製造方法及びｍｄｍ２阻害剤の結晶形 - Google Patents

製造方法及びｍｄｍ２阻害剤の結晶形 Download PDF

Info

Publication number
JP6998655B2
JP6998655B2 JP2016519576A JP2016519576A JP6998655B2 JP 6998655 B2 JP6998655 B2 JP 6998655B2 JP 2016519576 A JP2016519576 A JP 2016519576A JP 2016519576 A JP2016519576 A JP 2016519576A JP 6998655 B2 JP6998655 B2 JP 6998655B2
Authority
JP
Japan
Prior art keywords
cancer
chlorophenyl
added
mixture
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016519576A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016528179A (ja
JP2016528179A5 (enExample
Inventor
ビオ，マシュー
カイエ，セバスチャン
コクラン，ブライアン
ファン，ユエンチン
フォックス，ブライアン・エム
ルーカス，ブライアン・エス
マクギー，ローレンス・アール
ブーナトソス，フィリサティ
ビーデマン，ショーン
ワートマン，サラ
Original Assignee
アムジエン・インコーポレーテツド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51063849&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6998655(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by アムジエン・インコーポレーテツド filed Critical アムジエン・インコーポレーテツド
Publication of JP2016528179A publication Critical patent/JP2016528179A/ja
Publication of JP2016528179A5 publication Critical patent/JP2016528179A5/ja
Priority to JP2020084989A priority Critical patent/JP6891322B2/ja
Application granted granted Critical
Publication of JP6998655B2 publication Critical patent/JP6998655B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/25—Sulfonic acids having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/94—Oxygen atom, e.g. piperidine N-oxide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2016519576A 2013-06-10 2014-06-09 製造方法及びｍｄｍ２阻害剤の結晶形 Active JP6998655B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2020084989A JP6891322B2 (ja) 2013-06-10 2020-05-14 製造方法及びｍｄｍ２阻害剤の結晶形

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361833196P 2013-06-10 2013-06-10
US61/833,196 2013-06-10
PCT/US2014/041594 WO2014200937A1 (en) 2013-06-10 2014-06-09 Processes of making and crystalline forms of a mdm2 inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020084989A Division JP6891322B2 (ja) 2013-06-10 2020-05-14 製造方法及びｍｄｍ２阻害剤の結晶形

Publications (3)

Publication Number Publication Date
JP2016528179A JP2016528179A (ja) 2016-09-15
JP2016528179A5 JP2016528179A5 (enExample) 2017-07-20
JP6998655B2 true JP6998655B2 (ja) 2022-02-04

Family

ID=51063849

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016519576A Active JP6998655B2 (ja) 2013-06-10 2014-06-09 製造方法及びｍｄｍ２阻害剤の結晶形
JP2020084989A Active JP6891322B2 (ja) 2013-06-10 2020-05-14 製造方法及びｍｄｍ２阻害剤の結晶形
JP2021087378A Active JP7263439B2 (ja) 2013-06-10 2021-05-25 製造方法及びｍｄｍ２阻害剤の結晶形
JP2023064715A Pending JP2023089126A (ja) 2013-06-10 2023-04-12 製造方法及びｍｄｍ２阻害剤の結晶形
JP2025029906A Pending JP2025084856A (ja) 2013-06-10 2025-02-27 製造方法及びｍｄｍ２阻害剤の結晶形

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2020084989A Active JP6891322B2 (ja) 2013-06-10 2020-05-14 製造方法及びｍｄｍ２阻害剤の結晶形
JP2021087378A Active JP7263439B2 (ja) 2013-06-10 2021-05-25 製造方法及びｍｄｍ２阻害剤の結晶形
JP2023064715A Pending JP2023089126A (ja) 2013-06-10 2023-04-12 製造方法及びｍｄｍ２阻害剤の結晶形
JP2025029906A Pending JP2025084856A (ja) 2013-06-10 2025-02-27 製造方法及びｍｄｍ２阻害剤の結晶形

Country Status (38)

Country Link
US (10) US9376386B2 (enExample)
EP (3) EP3805232B1 (enExample)
JP (5) JP6998655B2 (enExample)
KR (4) KR20240159641A (enExample)
CN (3) CN110627708A (enExample)
AP (1) AP2015008891A0 (enExample)
AR (3) AR096582A1 (enExample)
AU (5) AU2014278428B2 (enExample)
BR (2) BR122020003153B1 (enExample)
CA (4) CA3201958A1 (enExample)
CL (3) CL2015003589A1 (enExample)
CR (2) CR20210290A (enExample)
CY (1) CY1123661T1 (enExample)
DK (1) DK3008039T3 (enExample)
EA (3) EA202091612A1 (enExample)
ES (2) ES3072074T3 (enExample)
HR (1) HRP20202065T1 (enExample)
HU (1) HUE053047T2 (enExample)
IL (4) IL297860A (enExample)
JO (2) JO3768B1 (enExample)
LT (1) LT3008039T (enExample)
MA (3) MA53572A1 (enExample)
MX (2) MX379872B (enExample)
MY (2) MY194848A (enExample)
NZ (1) NZ714821A (enExample)
PE (2) PE20160113A1 (enExample)
PH (2) PH12020550916A1 (enExample)
PL (1) PL3008039T3 (enExample)
PT (1) PT3008039T (enExample)
RS (1) RS61192B1 (enExample)
SG (2) SG11201509896VA (enExample)
SI (1) SI3008039T1 (enExample)
SM (1) SMT202100013T1 (enExample)
TN (1) TN2015000521A1 (enExample)
TW (3) TWI698428B (enExample)
UA (2) UA121301C2 (enExample)
UY (2) UY40179A (enExample)
WO (1) WO2014200937A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021130685A (ja) * 2013-06-10 2021-09-09 アムジエン・インコーポレーテツド 製造方法及びｍｄｍ２阻害剤の結晶形

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
US11407721B2 (en) 2013-02-19 2022-08-09 Amgen Inc. CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
MY192088A (en) 2013-11-11 2022-07-26 Amgen Inc Combinantion therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
CN109152843A (zh) 2016-05-20 2019-01-04 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
IL319432A (en) * 2018-04-30 2025-05-01 Kartos Therapeutics Inc Methods of treating cancer
US12268681B2 (en) * 2018-05-25 2025-04-08 Kartos Therapeutics, Inc. Methods of treating myeloproliferative neoplasms
CA3110525A1 (en) * 2018-08-31 2020-03-05 Amgen, Inc. Processes for preparing a mdm2 inhibitor
CN110963958B (zh) 2018-09-30 2025-10-10 上海长森药业有限公司 一种mdm2抑制剂，及其制备方法、药物组合物和应用
GB201919219D0 (en) 2019-12-23 2020-02-05 Otsuka Pharma Co Ltd Cancer biomarkers
US20230272001A1 (en) * 2020-05-22 2023-08-31 Merck Sharp & Dohme Llc Novel processes for preparing conjugates of the il-2 protein
JP2023539867A (ja) 2020-08-27 2023-09-20 大塚製薬株式会社 Ｍｄｍ２アンタゴニストを用いた癌治療に関するバイオマーカー
WO2022183006A1 (en) 2021-02-25 2022-09-01 Mayo Foundation For Medical Education And Research Compounds for programmable protein degradation and methods of use for the disease treatment
GB202103080D0 (en) 2021-03-04 2021-04-21 Otsuka Pharma Co Ltd Cancer biomarkers
US12054449B2 (en) 2021-08-05 2024-08-06 Bio-Pharm Solutions Co., Ltd. Phenylcarbamate crystalline form and method for manufacturing the same
EP4382509A4 (en) * 2021-08-05 2025-08-27 Bio Pharm Solutions Co Ltd CRYSTALLINE FORM OF PHENYLCARBAMATE AND PROCESS FOR ITS PREPARATION
EP4398903A4 (en) * 2021-09-09 2025-07-16 Kartos Therapeutics METHODS FOR TREATING CANCER DEPENDENT ON MYC GENE EXPRESSION
WO2023056069A1 (en) 2021-09-30 2023-04-06 Angiex, Inc. Degrader-antibody conjugates and methods of using same
CN115925589A (zh) * 2022-12-26 2023-04-07 诚达药业股份有限公司 一种脂肪族亚磺酸钙盐及其制备方法
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
JP2008545777A (ja) 2005-06-07 2008-12-18 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
US20090258904A1 (en) 2005-07-27 2009-10-15 Viranga Tillekeratne Epithiolone Analogues
US20110275586A1 (en) 2008-09-10 2011-11-10 Achaogen, Inc. Antibacterial aminoglycoside analogs
EP2386552A1 (en) 2010-05-11 2011-11-16 CBB Net S.A. Process for the preparation of (R) a-lipoic acid salts, their formulation and use in pharmaceutical compositions, in form of tablets containing them
WO2011153509A1 (en) 2010-06-04 2011-12-08 Amgen Inc. Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
WO2012097000A1 (en) 2011-01-10 2012-07-19 Pingda Ren Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2013002420A1 (en) 2011-06-29 2013-01-03 Otsuka Pharmaceutical Co., Ltd. Method for producing fine particles of aripiprazole anhydride crystals b
JP2013507391A (ja) 2009-10-09 2013-03-04 アカオジェン インコーポレイテッド 抗ウイルスアミノグリコシド類似体

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2483213A (en) * 1947-06-14 1949-09-27 American Cyanamid Co Alpha naphthalene sulfonic anhydride
CH436295A (de) 1961-11-13 1967-05-31 Mcneilab Inc Verfahren zur Herstellung neuer 3-Morpholinone
US3518236A (en) * 1967-07-20 1970-06-30 Uniroyal Inc Acceleration of sulfur-vulcanization of rubber with sulfinic acids and derivatives
DE3246148A1 (de) 1982-12-14 1984-06-14 Troponwerke GmbH & Co KG, 5000 Köln Pyrazolo(4.3-b)(1.4)oxazine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP2604472B2 (ja) 1989-07-12 1997-04-30 株式会社クラレ 重合性組成物
WO1995023135A1 (en) 1991-03-07 1995-08-31 Fisons Corporation Diphenyl-2-piperidinone and -2-pyrrolidinone derivatives having anti-convulsant and neuroprotective activity
US5334720A (en) 1991-03-07 1994-08-02 Fisons Corporation Diphenyl-1-(aminoalkyl)-2-piperidinone and -2-pyrrolidinone derivatives having anticonvulsant properties
AU711832B2 (en) 1994-08-19 1999-10-21 Abbvie Bahamas Ltd. Endothelin antagonists
ES2259803T3 (es) 1996-02-13 2006-10-16 Abbott Laboratories Nuevos derivados de pirrolidina sustituidos con benzo-1,3-dioxolilo y benzofuranilo como antagonistas de endostelina.
US6159990A (en) 1997-06-18 2000-12-12 Synaptic Pharmaceutical Corporation Oxazolidinones as α1A receptor antagonists
HUP0003484A3 (en) 1997-08-04 2002-02-28 Abbott Lab Pyrrolidine-3-crboxylic acid derivatives and their use as endothelin antagonists
AU1910299A (en) 1997-12-18 1999-07-05 Eli Lilly And Company Peptidomimetic template-based combinatorial libraries
US6770658B2 (en) 1998-09-09 2004-08-03 Inflazyme Pharmaceuticals Ltd. Substituted γ-phenyl-Δ-lactams and uses related thereto
US7214540B2 (en) * 1999-04-06 2007-05-08 Uab Research Foundation Method for screening crystallization conditions in solution crystal growth
US6630006B2 (en) * 1999-06-18 2003-10-07 The Regents Of The University Of California Method for screening microcrystallizations for crystal formation
US7195670B2 (en) * 2000-06-27 2007-03-27 California Institute Of Technology High throughput screening of crystallization of materials
US7052545B2 (en) * 2001-04-06 2006-05-30 California Institute Of Technology High throughput screening of crystallization of materials
DE19951418A1 (de) * 1999-10-26 2001-05-03 Merck Patent Gmbh Verfahren zur Herstellung von N-(4,5-Bismethansulfonyl-2-methyl-benzoyl) -guanidin, Hydrochlorid
WO2002017912A1 (en) 2000-08-31 2002-03-07 Abbott Laboratories Endothelin antagonists
US7229500B2 (en) * 2000-11-20 2007-06-12 Parallel Synthesis Technologies, Inc. Methods and devices for high throughput crystallization
HUP0304058A2 (hu) 2001-01-30 2004-04-28 Bristol-Myers Squibb Company Xa faktor szulfonamid-laktám inhibitorok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
CA2446380A1 (en) 2001-05-08 2002-11-14 Yale University Proteomimetic compounds and methods
WO2002094787A1 (en) 2001-05-23 2002-11-28 Ucb, S.A. 2-oxo-piperidinyl- and 2-oxo-azepanyl alkanoic acid derivativ es for the treatment of epilepsy and other neurological disorders
KR100650966B1 (ko) 2001-12-18 2006-11-30 에프. 호프만-라 로슈 아게 시스-2,4,5-트리페닐-이미다졸린 및 종양 치료에서의 그의용도
US6860940B2 (en) * 2002-02-11 2005-03-01 The Regents Of The University Of California Automated macromolecular crystallization screening
US6916833B2 (en) * 2003-03-13 2005-07-12 Hoffmann-La Roche Inc. Substituted piperidines
US7425638B2 (en) 2003-06-17 2008-09-16 Hoffmann-La Roche Inc. Cis-imidazolines
KR20080027969A (ko) 2004-05-18 2008-03-28 에프. 호프만-라 로슈 아게 신규 ｃｉｓ-이미다졸린
US7893278B2 (en) 2004-06-17 2011-02-22 Hoffman-La Roche Inc. CIS-imidazolines
JP4931823B2 (ja) 2004-10-18 2012-05-16 アムジエン・インコーポレーテツド チアジアゾール化合物及び使用方法
KR20130076903A (ko) 2005-02-18 2013-07-08 미쓰비시 타나베 파마 코퍼레이션 프롤린 유도체의 염 또는 그 용매화물 및 그 제조 방법
KR101139263B1 (ko) 2005-03-16 2012-05-16 에프. 호프만-라 로슈 아게 시스-２，４，５-트리아릴-이미다졸린 및 항암 약제로서의그의 용도
JP5180816B2 (ja) 2005-04-04 2013-04-10 エーザイ・アール・アンド・ディー・マネジメント株式会社 神経変性疾患および認知症のためのジヒドロピリジン化合物
CN101316823B (zh) 2005-12-01 2013-05-22 霍夫曼-拉罗奇有限公司 用作抗癌剂的作为p53和MDM2蛋白之间相互作用的抑制剂的2,4,5-三苯基咪唑啉衍生物
AU2007207743B2 (en) 2006-01-18 2010-07-08 Amgen Inc. Thiazole compounds as protein kinase B (PKB) inhibitors
US20070213341A1 (en) 2006-03-13 2007-09-13 Li Chen Spiroindolinone derivatives
WO2008005268A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
CA2657034A1 (en) 2006-07-19 2008-01-24 University Of Georgia Research Foundation, Inc. Pyridinone diketo acids: inhibitors of hiv replication in combination therapy
US20080045560A1 (en) 2006-08-15 2008-02-21 Wyeth Pyrrolidine and related derivatives useful as PR modulators
US7618989B2 (en) 2006-08-15 2009-11-17 Wyeth Tricyclic oxazolidone derivatives useful as PR modulators
TW200831080A (en) 2006-12-15 2008-08-01 Irm Llc Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
GB0722769D0 (en) 2007-11-21 2008-01-02 Biolipox Ab New compounds
CA2680783C (en) 2007-03-23 2012-04-24 Amgen Inc. Heterocyclic compounds and their uses
MX2009010050A (es) 2007-03-23 2009-10-12 Amgen Inc Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k).
HRP20160350T1 (hr) 2007-03-23 2016-05-06 Amgen Inc. Heterociklički spojevi i njihove uporabe
US7625895B2 (en) 2007-04-12 2009-12-01 Hoffmann-Le Roche Inc. Diphenyl-dihydro-imidazopyridinones
WO2008130614A2 (en) 2007-04-20 2008-10-30 University Of Pittsburg-Of The Commonwealth System Of Higher Education Selective and dual-action p53/mdm2/mdm4 antagonists
US7834179B2 (en) 2007-05-23 2010-11-16 Hoffmann-La Roche Inc. Spiroindolinone derivatives
WO2009004430A1 (en) 2007-06-29 2009-01-08 Pfizer Inc. N-benzyl oxazolidinones and related heterocycleic compounds as potentiators of glutamate receptors
WO2009007750A1 (en) 2007-07-09 2009-01-15 Astrazeneca Ab Morpholino pyrimidine derivatives used in diseases linked to mtor kinase and/or pi3k
US7919504B2 (en) 2007-07-17 2011-04-05 Amgen Inc. Thiadiazole modulators of PKB
US7897619B2 (en) 2007-07-17 2011-03-01 Amgen Inc. Heterocyclic modulators of PKB
US7928140B2 (en) 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
WO2009047161A1 (en) 2007-10-09 2009-04-16 F. Hoffmann-La Roche Ag Chiral cis-imidazolines
US7776875B2 (en) 2007-12-19 2010-08-17 Hoffman-La Roche Inc. Spiroindolinone derivatives
US7820665B2 (en) 2007-12-19 2010-10-26 Amgen Inc. Imidazopyridazine inhibitors of PI3 kinase for cancer treatment
EP2222296A2 (en) 2007-12-26 2010-09-01 Eisai R&D Management Co., Ltd. Ampa receptor antagonists and zonisamide for epilepsy
EP2268616A1 (en) 2008-03-21 2011-01-05 Chlorion Pharma, Inc. Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
JP5599783B2 (ja) 2008-05-30 2014-10-01 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
GB0811643D0 (en) 2008-06-25 2008-07-30 Cancer Rec Tech Ltd New therapeutic agents
AR073578A1 (es) 2008-09-15 2010-11-17 Priaxon Ag Pirrolidin-2-onas
CA2734363C (en) 2008-09-18 2016-10-25 F. Hoffmann-La Roche Ag Substituted pyrrolidine-2-carboxamides
WO2010083246A1 (en) 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
MX2011008674A (es) 2009-02-18 2011-11-04 Amgen Inc Compuestos de indol/bencimidazol como inhibidores de quinasa mtor.
CA2755285C (en) 2009-03-20 2014-02-11 Yunxin Y. Bo Inhibitors of pi3 kinase
US8076482B2 (en) 2009-04-23 2011-12-13 Hoffmann-La Roche Inc. 3,3′-spiroindolinone derivatives
UY32582A (es) 2009-04-28 2010-11-30 Amgen Inc Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
CA2760778A1 (en) 2009-05-13 2010-11-18 Amgen Inc. Heteroaryl compounds as pikk inhibitors
CA2781865A1 (en) 2009-06-25 2010-12-29 Amgen Inc. Polycyclic derivatives of pyridine and their use in the treatment of (inter alia) rheumatoid arthritis and similar diseases
CN102625799A (zh) 2009-06-25 2012-08-01 安姆根有限公司 杂环化合物及其用途
JP2012531435A (ja) 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド ＰＩ３Ｋ阻害剤としての４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オン誘導体
EP2445902A2 (en) 2009-06-25 2012-05-02 Amgen, Inc Heterocyclic compounds and their uses as inhibitors of pi3k activity
EA201200321A1 (ru) 2009-08-26 2012-09-28 Новартис Аг Тетразамещенные гетероарильные соединения и их применение в качестве модуляторов mdm2 и/или mdm4
US8088815B2 (en) 2009-12-02 2012-01-03 Hoffman-La Roche Inc. Spiroindolinone pyrrolidines
US8440693B2 (en) 2009-12-22 2013-05-14 Novartis Ag Substituted isoquinolinones and quinazolinones
WO2011100434A2 (en) * 2010-02-10 2011-08-18 Chistopher Su-Yan Own Aberration-correcting dark-field electron microscopy
CN102153557B (zh) 2011-01-21 2013-03-20 中国科学院上海有机化学研究所 具有乙二胺骨架的多手性中心氮杂环卡宾前体盐、合成方法及用途
TW201311938A (zh) * 2011-04-28 2013-03-16 大塚化學股份有限公司 偶氮二甲醯胺之新穎製造法
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
CN103373951B (zh) * 2012-04-28 2016-03-09 上海医药工业研究院 一种拉帕替尼中间体的制备方法
US20160002185A1 (en) 2013-02-19 2016-01-07 Amgen Inc. Cis-morpholinone and other compounds as mdm2 inhibitors for the treatment of cancer
WO2014134201A1 (en) 2013-02-28 2014-09-04 Amgen Inc. A benzoic acid derivative mdm2 inhibitor for the treatment of cancer
WO2014151863A1 (en) 2013-03-14 2014-09-25 Amgen Inc. Heteroaryl acid morpholinone compounds as mdm2 inhibitors for the treatment of cancer
MA53572A1 (fr) * 2013-06-10 2021-10-29 Amgen Inc Procédés de production et formes cristallines d'un inhibiteur mdm2

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007297283A (ja) 2004-07-28 2007-11-15 Santen Pharmaceut Co Ltd 新規桂皮酸関連化合物
JP2008545777A (ja) 2005-06-07 2008-12-18 ラモト アット テル アヴィヴ ユニヴァーシティ リミテッド コンジュゲート化された向精神薬の新規な塩およびその調製方法
US20090258904A1 (en) 2005-07-27 2009-10-15 Viranga Tillekeratne Epithiolone Analogues
US20110275586A1 (en) 2008-09-10 2011-11-10 Achaogen, Inc. Antibacterial aminoglycoside analogs
JP2013507391A (ja) 2009-10-09 2013-03-04 アカオジェン インコーポレイテッド 抗ウイルスアミノグリコシド類似体
EP2386552A1 (en) 2010-05-11 2011-11-16 CBB Net S.A. Process for the preparation of (R) a-lipoic acid salts, their formulation and use in pharmaceutical compositions, in form of tablets containing them
WO2011153509A1 (en) 2010-06-04 2011-12-08 Amgen Inc. Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
WO2012097000A1 (en) 2011-01-10 2012-07-19 Pingda Ren Processes for preparing isoquinolinones and solid forms of isoquinolinones
WO2013002420A1 (en) 2011-06-29 2013-01-03 Otsuka Pharmaceutical Co., Ltd. Method for producing fine particles of aripiprazole anhydride crystals b

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021130685A (ja) * 2013-06-10 2021-09-09 アムジエン・インコーポレーテツド 製造方法及びｍｄｍ２阻害剤の結晶形
JP7263439B2 (ja) 2013-06-10 2023-04-24 アムジエン・インコーポレーテツド 製造方法及びｍｄｍ２阻害剤の結晶形
JP2023089126A (ja) * 2013-06-10 2023-06-27 アムジエン・インコーポレーテツド 製造方法及びｍｄｍ２阻害剤の結晶形

Also Published As

Publication number Publication date
BR112015031004B1 (pt) 2022-09-20
PH12020550916A1 (en) 2024-03-25
NZ714821A (en) 2020-10-30
US20220280496A1 (en) 2022-09-08
MY205257A (en) 2024-10-09
KR20160018576A (ko) 2016-02-17
MA38714A1 (fr) 2017-10-31
EA202091612A1 (ru) 2020-10-05
AU2020267169B2 (en) 2022-08-25
KR20240159641A (ko) 2024-11-05
ES2851023T3 (es) 2021-09-02
TW202035370A (zh) 2020-10-01
CA3201958A1 (en) 2014-12-18
IL242622B (en) 2019-06-30
AR096582A1 (es) 2016-01-20
CA3115609C (en) 2023-08-08
HRP20202065T1 (hr) 2021-02-19
CN105358530A (zh) 2016-02-24
DK3008039T3 (da) 2021-01-04
US20160264526A1 (en) 2016-09-15
ES3072074T3 (en) 2026-06-29
EA201592305A1 (ru) 2016-05-31
NZ753956A (en) 2020-12-18
CN110003092A (zh) 2019-07-12
CA3115609A1 (en) 2014-12-18
WO2014200937A1 (en) 2014-12-18
US9855259B2 (en) 2018-01-02
EA031254B1 (ru) 2018-12-28
US20160287570A1 (en) 2016-10-06
AU2014278428B2 (en) 2018-11-15
PL3008039T3 (pl) 2021-04-19
CL2021000566A1 (es) 2021-09-03
IL266504B (en) 2021-04-29
SI3008039T1 (sl) 2021-03-31
TW201922705A (zh) 2019-06-16
AR132854A2 (es) 2025-08-06
BR112015031004A2 (pt) 2020-05-12
JP2021130685A (ja) 2021-09-09
AU2018260844B2 (en) 2020-08-13
MA43288B1 (fr) 2020-10-28
EP4778916A2 (en) 2026-07-22
JP2016528179A (ja) 2016-09-15
EP3805232A1 (en) 2021-04-14
AU2024216533A1 (en) 2024-09-19
CY1123661T1 (el) 2022-03-24
SG10201801402XA (en) 2018-04-27
TWI649306B (zh) 2019-02-01
EP3805232B1 (en) 2026-04-22
PE20160113A1 (es) 2016-03-03
CR20160010A (es) 2016-02-04
CL2015003589A1 (es) 2016-06-17
AU2020267169A1 (en) 2020-12-03
AU2014278428A1 (en) 2015-11-26
KR20210121270A (ko) 2021-10-07
AP2015008891A0 (en) 2015-11-30
TN2015000521A1 (en) 2017-04-06
TWI791153B (zh) 2023-02-01
CL2019000056A1 (es) 2019-05-03
AR119727A2 (es) 2022-01-05
RS61192B1 (sr) 2021-01-29
TW201536743A (zh) 2015-10-01
MX2019012007A (es) 2019-11-11
SMT202100013T1 (it) 2021-03-15
IL297860A (en) 2023-01-01
JP2025084856A (ja) 2025-06-03
JP2020147573A (ja) 2020-09-17
CR20210290A (es) 2021-07-23
JP7263439B2 (ja) 2023-04-24
JP6891322B2 (ja) 2021-06-18
PH12015502705A1 (en) 2016-03-14
CA3200532A1 (en) 2014-12-18
IL281807A (en) 2021-05-31
TWI698428B (zh) 2020-07-11
US9801867B2 (en) 2017-10-31
LT3008039T (lt) 2021-01-25
PE20210153A1 (es) 2021-01-26
CN110627708A (zh) 2019-12-31
IL242622A0 (en) 2016-02-01
JP2023089126A (ja) 2023-06-27
US9623018B2 (en) 2017-04-18
US20160289190A1 (en) 2016-10-06
AU2022271425A1 (en) 2022-12-22
MX379872B (es) 2025-03-11
UA121301C2 (uk) 2020-05-12
US20230301974A1 (en) 2023-09-28
HUE053047T2 (hu) 2021-06-28
SG11201509896VA (en) 2016-01-28
EA201891642A1 (ru) 2019-08-30
JO3768B1 (ar) 2021-01-31
US20160289243A1 (en) 2016-10-06
US20200281912A1 (en) 2020-09-10
BR122020003153B1 (pt) 2022-09-27
UY40179A (es) 2023-04-14
UA129695C2 (uk) 2025-07-09
JOP20200296A1 (ar) 2020-11-22
AU2022271425B2 (en) 2024-06-13
PT3008039T (pt) 2021-01-13
US9376386B2 (en) 2016-06-28
MA53572A1 (fr) 2021-10-29
PH12015502705B1 (en) 2022-04-27
IL281807B2 (en) 2023-04-01
KR20230019216A (ko) 2023-02-07
IL266504A (en) 2019-07-31
US20140364455A1 (en) 2014-12-11
CA2914723A1 (en) 2014-12-18
CA2914723C (en) 2021-06-15
MA43288A1 (fr) 2020-04-30
AU2018260844A1 (en) 2018-11-22
US9757367B2 (en) 2017-09-12
IL281807B (en) 2022-12-01
MX2015016856A (es) 2016-04-07
MY194848A (en) 2022-12-19
UY35605A (es) 2015-01-30
EP3008039B1 (en) 2020-11-11
EP3008039A1 (en) 2016-04-20
US20180092898A1 (en) 2018-04-05
US20160289178A1 (en) 2016-10-06

Similar Documents

Publication Publication Date Title
JP6891322B2 (ja) 製造方法及びｍｄｍ２阻害剤の結晶形
US20250295647A1 (en) Processes of making and crystalline forms of a mdm2 inhibitor
HK40050580A (en) Crystalline synthetic intermediate useful in processes for making a mdm2 inhibitor
KR20210052497A (ko) Mdm2 억제제의 제조 방법
NZ753956B2 (en) Processes of making and crystalline forms of a mdm2 inhibitor
HK1226052B (en) Crystalline form of a mdm2 inhibitor
HK1226052A1 (en) Crystalline form of a mdm2 inhibitor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180515

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180809

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190305

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200114

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20200514

C116 Written invitation by the chief administrative judge to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C116

Effective date: 20200526

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20200526

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210209

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210413

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20210618

C305 Report on accelerated appeal examination

Free format text: JAPANESE INTERMEDIATE CODE: C305

Effective date: 20210628

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20210629

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20210713

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211013

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20211026

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20211124

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20211124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211221

R150 Certificate of patent or registration of utility model

Ref document number: 6998655

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250